Endocrine Responsive Early Breast Cancer Clinical Trial
Insomnia is common in Breast cancer patients during adjuvant therapy with aromatase
inhibitor.
However it is difficult to establish whether it is due to the knowledge of the disease or
the treatment administred.
The investigators designed a cohort study in which questionnaires for the assessment of
sleep quality (Pittsburgh Sleep Quality Index and Insomnia Severity Index), anxiety (State
and Trait Anxiety Inventory), depression (Beck Depression Inventory), for the quality of
life in general (Functional Assessment of Cancer Therapy) and for the evaluation of RLS
(Restless Legs Syndrome Rating Scale) will be prospectively administered to patients with
early breast cancer at baseline and during adjuvant treatment with aromatase inhibitors.
As secondary aims the investigators will also evaluate dietary and lifes' factors, born turn
over and BMI.
n/a
Observational Model: Case-Only, Time Perspective: Prospective